Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Insys Therapeutics history
Insys Therapeutics company history timeline
There have been nearly 218,000 overdose deaths related to prescription opioids since OxyContin was introduced in 1996, according to the Centers for Disease Control and Prevention.
One of the few other criminal cases against drug company executives involved another opioid manufacturer, Purdue Pharma, whose executives pleaded guilty in 2007 to criminal charges that they misled regulators, doctors and patients about the addiction potential of the painkiller OxyContin.
The historic case, which included indictments going back to 2016, centered on a fentanyl-based pain medication called Subsys, a powerful, highly addictive and potentially dangerous narcotic intended to treat patients with cancer suffering from intense pain.
Last month, the company — which also sells a liquid form of an anti-nausea drug derived from cannabis — announced it was replacing its president and chief executive, Saeed Motahari, who had joined the company in 2017.
Kapoor's 2017 arrest came on the same day that President Donald Trump declared the epidemic a public emergency.
In 2017, more than 28,000 of the nation's overdose deaths involved synthetic opioids, according to the Centers for Disease Control and Prevention.
Rate Insys Therapeutics' efforts to communicate its history to employees.
Insys Therapeutics jobs
Do you work at Insys Therapeutics?
Is Insys Therapeutics' vision a big part of strategic planning?
Insys Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Amneal Pharmaceuticals | 2002 | $2.8B | 6,500 | 101 |
| Merck | 1891 | $64.2B | 74,000 | 2,627 |
| Quidel | 1979 | $1.7B | 1,500 | - |
| Seagen | 1997 | $2.0B | 900 | - |
| Amgen | 1980 | $33.4B | 22,000 | 713 |
| Regeneron | 1988 | $14.2B | 9,123 | 430 |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 624 |
| Neurocrine Biosciences | 1992 | $2.4B | 400 | 337 |
| Paddock Laboratories | 1977 | $100.5M | 51 | - |
| Shionogi | 1878 | $50.0M | 6,082 | 208 |
Insys Therapeutics history FAQs
Zippia gives an in-depth look into the details of Insys Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Insys Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Insys Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Insys Therapeutics. The data presented on this page does not represent the view of Insys Therapeutics and its employees or that of Zippia.
Insys Therapeutics may also be known as or be related to INSYS THERAPEUTICS INC., INSYS Therapeutics Inc, INSYS Therapeutics, Inc., Insys RX, Insys Therapeutics, Insys Therapeutics Inc. and Insys Therapeutics, Inc.